BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20890555)

  • 1. [Quality of vaginal smear for cervical cancer screening: a concordance study].
    Cendales R; Wiesner C; Murillo RH; Piñeros M; Tovar S; Mejía JC
    Biomedica; 2010; 30(1):107-15. PubMed ID: 20890555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common problems in Papanicolaou smear interpretation.
    DeMay RM
    Arch Pathol Lab Med; 1997 Mar; 121(3):229-38. PubMed ID: 9111106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical analysis of data in cervical cytology from the viewpoint of total quality management.
    Kaminsky FC; Burke RJ; Haberle KR; Mullins DL
    Acta Cytol; 1995; 39(2):222-31. PubMed ID: 7887069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Plea for quality cytological specimens in the screening of cervical cancer].
    Marie G; Barjot P; Crouet H; von Theobald P; Soutif C; Levy G
    Rev Fr Gynecol Obstet; 1993 Jun; 88(6):365-7. PubMed ID: 8351458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low proportion of false-negative smears in the Finnish program for cervical cancer screening.
    Lönnberg S; Anttila A; Kotaniemi-Talonen L; Kujari H; Melkko J; Granroth G; Vornanen M; Pietiläinen T; Sankila A; Arola J; Luostarinen T; Nieminen P
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):381-7. PubMed ID: 20142239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality and liability issues with the Papanicolaou smear: the problem of definition of errors and false-negative smears.
    Davey DD
    Arch Pathol Lab Med; 1997 Mar; 121(3):267-9. PubMed ID: 9111115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive evaluation of cervical cancer screening programs: the case of Colombia.
    Murillo R; Wiesner C; Cendales R; Piñeros M; Tovar S
    Salud Publica Mex; 2011; 53(6):469-77. PubMed ID: 22282139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papanicolaou cervical smears for screening in asymptomatic women.
    Barnes BA
    Prim Care; 1981 Mar; 8(1):131-40. PubMed ID: 6911755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinded review of papanicolaou smears.
    Frable WJ
    Cancer; 2004 Jun; 102(3):133-5. PubMed ID: 15211470
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cervical smears unsuitable for exclusion of cervical carcinoma].
    Giard RW; Blok P
    Ned Tijdschr Geneeskd; 2000 Jan; 144(2):86-7. PubMed ID: 10674109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process.
    Renshaw AA; DiNisco SA; Minter LJ; Cibas ES
    Cancer; 1997 Oct; 81(5):272-6. PubMed ID: 9349513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should adequacy of liquid-based cytology be defined?
    Desai M; Herbert A
    Cytopathology; 2006 Aug; 17(4):165-7. PubMed ID: 16879262
    [No Abstract]   [Full Text] [Related]  

  • 13. ["Papanicolaou." Outmoded, isn't it?].
    de León-Antoni E
    Bol Asoc Med P R; 1991 Oct; 83(10):462-4. PubMed ID: 1789893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing cervical cancer mortality in Mexico: effect of Papanicolaou coverage, birthrate, and the importance of diagnostic validity of cytology.
    Lazcano-Ponce E; Palacio-Mejia LS; Allen-Leigh B; Yunes-Diaz E; Alonso P; Schiavon R; Hernandez-Avila M
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2808-17. PubMed ID: 18843027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution of the Papanicolaou smear.
    Tambouret RH
    Clin Obstet Gynecol; 2013 Mar; 56(1):3-9. PubMed ID: 23314726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The false-negative fraction for Papanicolaou smears: how often are "abnormal" smears not detected by a "standard" screening cytologist?
    Naryshkin S
    Arch Pathol Lab Med; 1997 Mar; 121(3):270-2. PubMed ID: 9111116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid pre-screening of cervical smears as a method of internal quality control in a cervical screening programme.
    Tavares SB; de Sousa NL; Manrique EJ; de Albuquerque ZB; Zeferino LC; Amaral RG
    Cytopathology; 2008 Aug; 19(4):254-9. PubMed ID: 18476988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liability issues with the Papanicolaou smear: a defense lawyer's perspective.
    Varner CD
    Arch Pathol Lab Med; 1997 Mar; 121(3):315-20. PubMed ID: 9111126
    [No Abstract]   [Full Text] [Related]  

  • 19. External quality control of cervical cytopathology: interlaboratory variability.
    Azara CZ; Manrique EJ; Alves de Souza NL; Rodrigues AR; Tavares SB; Amaral RG
    Acta Cytol; 2013; 57(6):585-90. PubMed ID: 24107687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does a zero error standard exist for the Papanicolaou smear? A pathologist's perspective.
    Frable WJ
    Arch Pathol Lab Med; 1997 Mar; 121(3):301-10. PubMed ID: 9111124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.